Global /Italy /Healthcare /Biotechnology /UBM
chevron_leftBack
Helyx Industries S.p.A. logo

Helyx Industries S.p.A.

UBM
MIL: UBM Delayed
0.6280EUR -0.3%
0.7294 USD
As of 5 June 2026, Helyx Industries S.p.A. has a market cap of $19.03M USD, ranking #37449 globally and #305 in Italy. It ranks #3354 in the Healthcare sector, and #661 in the Biotechnology industry.
Global Rank
37449
Country Rank
305
Sector Rank
3354
Industry Rank
661
Key Stats
Market Cap
$19.03MUSD
16.41M EUR
Enterprise Value
$18.9MUSD
16.27M EUR
Revenue (TTM)
$2.24MUSD
1.93M EUR
EBITDA (TTM)
-$1.82MUSD
-1.57M EUR
Net Income (TTM)
-$5.08MUSD
-4.38M EUR
EBITDA Margin
-81%
Profit Margin
-227%
PS Ratio
8.5
PB Ratio
0.8
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Nicola Basile open_in_new
Employees
18
Founded
2015
Website
helyx.bio open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-0.3% 1.3% -11% -19% -40% -16%

News

Loading...

Markets

Exchange Ticker Price
Borsa Italiana
MIC: XMIL
PRIMARY
UBM
Ulisse Biomed SpA
ISIN: IT0005451213
Shares Out.:
25.51M1
TV:
SA:
YF:
GF:
BA:
UBM
MS:
0.6280 EUR
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Helyx Industries S.p.A.

Helyx Industries S.p.A., a healthcare biotech company, develops, produces, and markets vitro diagnostic medical devices in Italy. The company through its Sagitta platform offers various tests, such as Ladymed/HPV Selfy for the detection of human papillomavirus (HPV); CoronaMelt, a diagnostic test for Sars- CoV-2; CoronaMelt Var, a diagnostic assay for the detection and genotyping of Sars-CoV-2 variants; and UlisseFaster, a reagent for the pre-treatment of biological samples. It provides various tests and reagents for sexually transmitted diseases and HPV. In addition, the company’s platforms also comprise NanoHybrid, a platform to detect specific antibodies and protein analytes directly from serum or whole blood; and Aptavir platform to develop and produce synthetic nucleic acid molecules to limit the infectivity of pathogens. The company was formerly known as Ulisse Biomed S.p.A. and change its name to Helyx Industries S.p.A. in December 2025. Helyx Industries S.p.A. was founded in 2015 and is based in Udine, Italy.

Similar Companies

Industry: Biotechnology (Italy)
Name
Market Cap diff.
PE
$23.63M
20.37M EUR
24%
15.2
Industry: Biotechnology (Global)
Name
Market Cap diff.
PE
AMGN
$182.42B
958K%
23.9
GILD
$159.92B
840K%
19.0
ARGX
$48.01B
41.39B EUR
252K%
39.9
$44.48B
68.19T KRW
234K%
35.5
CSL
$43.01B
60.27B AUD
226K%
29.3
LONN
$42.55B
33.71B CHF
223K%
37.2
chevron_leftBack